Rating Rationale
September 07, 2020 | Mumbai
B. Braun Medical India Private Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.100 Crore
Long Term Rating CRISIL BBB/Stable (Reaffirmed)
Short Term Rating CRISIL A3+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its ratings on the bank loan facilities of B. Braun Medical India Private Limited (BBMI: part of B-Braun India group) at 'CRISIL BBB/Stable/CRISIL A3+'.
 
The ratings continue to reflect the strong operational, technical, and funding support from the ultimate parent company: B. Braun Melsungen AG (BBMAG), a sound track record, and a strong distribution network and brand in the healthcare consumables segment. These strengths are partially offset by weak operating efficiency, and exposure to intense competition and adverse impact of government policies.

Analytical Approach

For arriving at the ratings, CRISIL has combined the business and financial risk profiles of BBMI and its subsidiaries, Oyster Medisafe Pvt Ltd (OMPL), AG Infrastructure Pvt Ltd, and WhiteINC Space Pvt Ltd. That's because all these companies are under the same management.
 
Further, CRISIL has applied its parent notch-up to the standalone rating of BBMI as the company is a majority-owned subsidiary of BBMAG.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths
* Strategic importance to, and strong expectation of support from, BBMAG: BBMAG, which is ultimate parent of B-Braun India group, is also its key supplier. Almost entire material is supplied by BBMAG. Furthermore, its strong and established market position in the healthcare equipment market will support the business risk profile of B-Braun India. Also, BBMAG has provided a corporate guarantee against its debt and has been supporting funding requirement. Owing to B-Braun India group's criticality to BBMAG's operations and the latter's robust financial risk profile and ample liquidity, continued funding support is likely.
 
* Established distribution network and brand: BBMI has a pan-India distribution network and strong brand equity in the global healthcare consumables segment. This is reflected in strong operating income of Rs 509.59 crores in FY2020. Operating income in FY2020 however has been lower than Rs 542.50 crore in FY2019 due to weak performance in March 2020 owing to nationwide lockdown to contain the spread of Covid-19.
 
Weaknesses
* Weak Operating efficiency: In the past two fiscals, the group has invested in additional capacities however due to limited offtake, the same remains under-utilised which is impacting the operating margins. Operating efficiency of the group has remained weak marked by further fall in EBITDA from 1% in FY 2019 to -1% estimated in FY 2020 and ROCE remains negative in this period. Additionally, working capital requirements are high owing to stretch in payments from customers like State Governments and large hospitals, and this is reflected in gross current assets estimated at 167 days as on March 31, 2020. The provisions against stretched debtors are made, which has constrained overall operating efficiencies. Going ahead, with muted growth in revenue, operating margins are expected to remain weak over the medium term.

Subdued operating performance in recent past has led to deterioration in group's financial risk profile, marked by further reduction in net worth from Rs 6.91 crores as on 31st March 2019 to Rs (42.95) crore estimated as on 31st March 2020 and hence leading to negative gearing. The capital structure has deteriorated due to increase in reliance on external debt which is utilised to fund losses. The group has recently received enhancements in working capital limit, increased from Rs 310.5 crore to Rs 331 crore, which continues to remain highly utilized. With expected muted business performance, the financial risk profile is expected to remain average over the medium term.

B. Braun Medical Industries Sdn Bhd, Malaysia - immediate parent - is also expected to infuse additional equity (~Rs.130 crore) in BBMI by December 2020; this should improve the capital structure of the company. Timely infusion of this equity is critical in nature due to the losses that company has made in recent past which has also wiped out the networth.
 
* Exposure to intense competition and susceptibility to changes in government regulations: The domestic medical equipment market is dominated by top three players: GE Healthcare (a division of General Electric Company USA), Philips Healthcare (a division of Koninklijke Philips Electronics NV), and Siemens Healthcare (a division of Siemens AG). BBMI does not supply products manufactured by any of these top players, leading to a relatively small market share. Moreover, the regulated nature of the medical devices sector restricts revenue and profitability as the final prices of most of the products are controlled by government authorities. Revenue and operating margin will remain susceptible to intense competition and changes in government policies and regulations.
Liquidity Adequate

The cash accrual remains negative at Rs 12.75 crore in fiscal 2020, constraining it liquidity. However, the timely enhancement in working capital limits has supported its liquidity. Average utilisation of the bank limit was moderate at around 88% during the 8 months ended July 2020. B. Braun Medical Industries Sdn Bhd, Malaysia ' immediate parent ' is also expected to infuse additional equity (~Rs.130 crore) in BBMI by December 2020; this should support the liquidity of the company. Funding support from parent along with improvement in cash accruals is critical and hence remains a key rating sensitivity going ahead.

Outlook: Stable

CRISIL believes the credit risk profile of the company will remain constrained over the medium term due to a weak operational performance, though it would remain supported by a strong parent.
 
Rating Sensitivity Factors
Upward factors
* Significant and sustained improvement in the operating margin to around 10% along with increase in the scale of operations leading to positive net cash accruals
* Significant improvement in financial risk profile
 
Downward factors
* Decline in revenue by 20% or operating profitability continues to remain negative
* Delayed equity infusion or weakening of BBMAG's financial risk profile.

About the Company

BBMI was incorporated in 1994 as a 99.99% subsidiary of B Braun Medical Industries Sdn Bhd, Malaysia, which is a subsidiary of BBMAG, the flagship company of the B Braun group. The group, which has a presence in 62 countries, manufactures surgical sutures, parenterals, syringes, needles, intravenous catheters, intravenous solutions, surgical instruments, orthopaedic implants, devices to check sugar level, and surgical gloves, among others. Except sutures, BBMI imports all these products from its affiliates and supplies them to hospitals and nursing homes in India. The company has a manufacturing facility in Chennai for sutures, which it exports to affiliates. In March 2011, it acquired a majority stake in OMPL.

Key Financial Indicators
As on/for the period ended March 31 Units 2020 2019
Operating income Rs.Crore 509.59 542.50
Reported profit after tax (PAT) Rs.Crore -49.87 -20.86
PAT margin % -9.8 -3.8
Adjusted debt/adjusted networth Times -6.09 29.05
Interest coverage Times 0.27 0.34

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon
Rate (%)
Maturity Date Issue Size (Rs.Cr) Complexity Level Rating Assigned with Outlook
NA Bank Guarantee NA NA NA 10 NA CRISIL A3+
NA Cash Credit/ Overdraft facility NA NA NA 54 NA CRISIL BBB/Stable
NA Proposed Working Capital Facility NA NA NA 16 NA CRISIL BBB/Stable
NA Fund & Non Fund Based Limits NA NA NA 4 NA CRISIL BBB/Stable
NA Working Capital Facility NA NA NA 16 NA CRISIL BBB/Stable
 
Annexure - List of Entities Consolidated
Names of Entities Consolidated Extent of Consolidation Rationale for Consolidation
B. Braun Medical India Private Limited 100% Holding company
Oyster Medisafe Private Limited 100% Majority shareholding along with operational linkages
WhiteINC Space Pvt Ltd 100% Wholly owned subsidiary
AG Infrastructure Pvt Ltd 100% Wholly owned subsidiary
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  86.00  CRISIL BBB/Stable  30-01-20  CRISIL BBB/Stable      24-10-18  CRISIL BBB+/Stable  30-06-17  CRISIL A-/Stable  CRISIL A-/Stable/ CRISIL A2+ 
Non Fund-based Bank Facilities  LT/ST  14.00  CRISIL BBB/Stable/ CRISIL A3+  30-01-20  CRISIL BBB/Stable/ CRISIL A3+      24-10-18  CRISIL A2  30-06-17  CRISIL A2+  CRISIL A2+ 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 10 CRISIL A3+ Bank Guarantee 10 CRISIL A3+
Cash Credit/ Overdraft facility 54 CRISIL BBB/Stable Cash Credit/ Overdraft facility 54 CRISIL BBB/Stable
Fund & Non Fund Based Limits 4 CRISIL BBB/Stable Fund & Non Fund Based Limits 4 CRISIL BBB/Stable
Proposed Working Capital Facility 16 CRISIL BBB/Stable Proposed Working Capital Facility 16 CRISIL BBB/Stable
Working Capital Facility 16 CRISIL BBB/Stable Working Capital Facility 16 CRISIL BBB/Stable
Total 100 -- Total 100 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Criteria for rating trading companies
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt
Criteria for Notching up Stand Alone Ratings of Companies based on Parent Support

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Mohit Makhija
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
mohit.makhija@crisil.com


Smriti Singh
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 4040 8416
Smriti.Singh@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL